Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting

Brain metastases are a common and serious complication among patients with metastatic melanoma. The selective BRAF inhibitor vemurafenib has demonstrated clinical efficacy in patients with BRAF V600E-mutant melanoma brain metastases (MBM). We examined the real-world application and clinical outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales: Gibney, Geoffrey T, Gauthier, Geneviève, Ayas, Charles, Galebach, Philip, Wu, Eric Q, Abhyankar, Sarang, Reyes, Carolina, Guérin, Annie, Yim, Yeun Mi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559032/
https://www.ncbi.nlm.nih.gov/pubmed/25991583
http://dx.doi.org/10.1002/cam4.475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559032/
https://www.ncbi.nlm.nih.gov/pubmed/25991583
http://dx.doi.org/10.1002/cam4.475

Ejemplares similares